+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Disease Stage (Advanced Stage, Early Stage), Treatment Line, Molecule Type, Patient Age - Global Forecast 2025-2030- Product Image
Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Disease Stage (Advanced Stage, Early Stage), Treatment Line, Molecule Type, Patient Age - Global Forecast 2025-2030- Product Image
Sale

Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiotherapy), Disease Stage (Advanced Stage, Early Stage), Treatment Line, Molecule Type, Patient Age - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715559
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hodgkin Lymphoma Treatment Market is entering a period of significant transformation, driven by advanced therapies, targeted innovations, and evolving care strategies. Senior executives will find this analysis essential for understanding key shifts affecting clinical outcomes, operational strategy, and future growth prospects in a complex healthcare landscape.

Market Snapshot: Hodgkin Lymphoma Treatment Market

The Hodgkin Lymphoma Treatment Market grew from USD 1.31 billion in 2024 to USD 1.43 billion in 2025. It is expected to continue growing at a CAGR of 9.28%, reaching USD 2.23 billion by 2030.

Scope & Segmentation of the Hodgkin Lymphoma Treatment Market

  • Treatment Types: Chemotherapy (including ABVD regimen, BEACOPP regimen, liposomal formulations), Immunotherapy, Radiotherapy (adaptive, involved-field, proton), Targeted Therapy
  • Disease Stages: Early stage (Stage I, Stage II), Advanced stage (Stage III, Stage IV)
  • Treatment Lines: First line, Second line, Third line
  • Molecule Types: Monoclonal antibodies (CD30-directed therapies such as brentuximab vedotin, next-generation antibodies, PD-1 inhibitors including nivolumab and pembrolizumab), Small molecules (histone deacetylase inhibitors, next-generation HDAC inhibitors, romidepsin, vorinostat)
  • Patient Demographics: Adult, Geriatric, Pediatric
  • Geographies Covered: Americas, Europe, Middle East & Africa, Asia-Pacific

This segmentation highlights the market’s diversity, from treatment methodologies and disease progression to therapeutic agents and demographic considerations, ensuring a comprehensive view for effective portfolio and investment decisions.

Key Takeaways for Decision Makers

  • Therapeutic innovation is redefining the standard of care, with increased use of immunotherapies and targeted agents supporting a shift towards personalized medicine in Hodgkin lymphoma treatment.
  • Risk-adaptive and precision diagnostic approaches are fostering improved survival rates, while also emphasizing reductions in long-term patient toxicity and quality of life enhancements.
  • Next-generation sequencing, digital pathology, and AI-driven imaging are enabling earlier intervention, stratified treatment, and real-time decision-making, strengthening clinical and business outcomes.
  • Collaborative care models and strategic partnerships among hematologists, oncologists, and diagnostic specialists are supporting holistic patient management and facilitating entry of novel therapeutics.
  • Regional variations in regulatory policies, access to innovation, and payer engagement require tailored market entry and reimbursement strategies across different geographies.

Tariff Impact: Responding to U.S. Policy Shifts

Beginning in 2025, United States tariffs have introduced added pressures on supply chain models for Hodgkin lymphoma treatments. Pharmaceutical and biotech companies face increased costs for imported active pharmaceutical ingredients, leading to strategic changes such as renegotiating supplier agreements, optimizing procurement, and localizing production where feasible. These dynamics prompt leaner inventory strategies, heightened logistics coordination, and a proactive stance toward policy and trade developments, all of which are critical to maintaining product availability and cost stability.

Methodology & Data Sources

This report utilizes a blended approach of primary and secondary research methods. Primary interviews with clinicians, policy experts, and supply chain executives provide real-world perspectives. Secondary research draws from peer-reviewed literature, regulatory files, proprietary databases, and healthcare data repositories. Analytical frameworks such as SWOT analysis and scenario planning underpin market forecasts and competitive assessment, ensuring insight reliability and data integrity.

Why This Report Matters: Executive Value

  • Informs strategic planning by highlighting trends in therapeutic advancement, segmented market analysis, and evolving stakeholder requirements in Hodgkin lymphoma care.
  • Equips leaders to assess risk, policy impact, and growth opportunities—supporting data-driven decisions on regional entry, R&D allocation, and supply chain resiliency.

Conclusion

The Hodgkin Lymphoma Treatment Market continues to evolve amid technological breakthroughs, regulatory changes, and shifting demand patterns. For decision makers, an informed response guided by robust analysis will enable effective adaptation and deliver improved outcomes in the face of ongoing market transformation.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of PD-1 checkpoint inhibitors into frontline therapy protocols for refractory Hodgkin lymphoma patients
5.2. Adoption of CD30-directed CAR T-cell therapies in relapsed or refractory Hodgkin lymphoma treatment landscapes
5.3. Emerging role of circulating tumor DNA assays to monitor minimal residual disease and guide Hodgkin lymphoma therapy
5.4. Impact of biosimilar brentuximab vedotin entries on pricing dynamics and access to advanced Hodgkin lymphoma therapies
5.5. Increasing utilization of real-world evidence studies to assess long-term safety outcomes in Hodgkin lymphoma survivors
5.6. Development of bispecific antibodies targeting PD-1 and CD30 to enhance immunotherapeutic efficacy in Hodgkin lymphoma
5.7. Expansion of combination regimens merging checkpoint inhibitors with salvage chemotherapy in relapsed Hodgkin lymphoma patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hodgkin Lymphoma Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Abvd Regimen
8.2.2. Beacopp Regimen
8.2.3. Liposomal Formulations
8.3. Immunotherapy
8.4. Radiotherapy
8.4.1. Adaptive Radiotherapy
8.4.2. Involved-Field Radiotherapy
8.4.3. Proton Radiotherapy
8.5. Targeted Therapy
9. Hodgkin Lymphoma Treatment Market, by Disease Stage
9.1. Introduction
9.2. Advanced Stage
9.2.1. Stage III
9.2.2. Stage IV
9.3. Early Stage
9.3.1. Stage I
9.3.2. Stage II
10. Hodgkin Lymphoma Treatment Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Hodgkin Lymphoma Treatment Market, by Molecule Type
11.1. Introduction
11.2. Monoclonal Antibodies
11.2.1. Cd30 Directed Antibodies
11.2.1.1. Brentuximab Vedotin
11.2.1.2. Next Generation Antibodies
11.2.2. Pd-1 Inhibitors
11.2.2.1. Nivolumab
11.2.2.2. Pembrolizumab
11.3. Small Molecules
11.3.1. Histone Deacetylase Inhibitors
11.3.1.1. Next Generation Hdac Inhibitors
11.3.1.2. Romidepsin
11.3.1.3. Vorinostat
12. Hodgkin Lymphoma Treatment Market, by Patient Age
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Hodgkin Lymphoma Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hodgkin Lymphoma Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hodgkin Lymphoma Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. Bristol-Myers Squibb Company
16.3.3. Merck & Co., Inc.
16.3.4. Gilead Sciences, Inc.
16.3.5. Novartis AG
16.3.6. Roche Holding AG
16.3.7. Johnson & Johnson
16.3.8. Pfizer Inc.
16.3.9. Seagen Inc.
16.3.10. Kite Pharma, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHAI
FIGURE 26. HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 165. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 166. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 167. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 168. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 169. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 170. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 171. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 172. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 173. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 174. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 175. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 176. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 177. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 178. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 179. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 180. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 181. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 182. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 183. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 184. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 185. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 186. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 187. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 188. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 189. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 190. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 191. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 192. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 193. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 196. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 197. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 198. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 199. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 204. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 205. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 206. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 207. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 210. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 211. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 212. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 213. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 216. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 217. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 218. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 219. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 220. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hodgkin Lymphoma Treatment market report include:
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Roche Holding AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Seagen Inc.
  • Kite Pharma, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.43 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.23 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cell Type (B-cell Lymphomas, NK-cell Lymphomas, T-cell Lymphomas), Route of Administration, Patient Age Group, End User - Global Forecast 2025-2030 - Product Image

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cell Type (B-cell Lymphomas, NK-cell Lymphomas, T-cell Lymphomas), Route of Administration, Patient Age Group, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Hodgkins Lymphoma Treatment - Global Strategic Business Report - Product Image

Hodgkins Lymphoma Treatment - Global Strategic Business Report

  • Report
  • 127 Pages
  • Global
From
Hodgkin Lymphoma Drug Pipeline Analysis Report 2025 - Product Image

Hodgkin Lymphoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Hodgkin's Lymphoma- Pipeline Insight, 2025 - Product Image

Hodgkin's Lymphoma- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Lymphoma Therapeutics Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Product Type (Branded, Generic), Disease Type, End User, Age Group, Distribution Channel - Global Forecast 2025-2030 - Product Image

Lymphoma Therapeutics Market by Therapy Type (Chemotherapy, Immunotherapy, Radiation Therapy), Product Type (Branded, Generic), Disease Type, End User, Age Group, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.